Evidence Sheet: Bank Of America Corp /de/ (BAC)
The standing BullScope yardsticks for Bank Of America Corp /de/, computed from official filings and refreshed with each new edition.
Target’s Revenue Has Shrunk for Three Straight Years. Its Stock Just Hit a 52-Week High.
Target built its modern identity on a simple promise: the cheap-chic discount store where a family could grab groceries, a...
Bank of America Is Priced for a Bank It Has Never Quite Been
The stock is trading near a decade high. The earnings multiple sits at its 81st percentile against its own ten-year...
Evidence Sheet: Apple (AAPL)
The standing BullScope yardsticks for Apple, computed from official filings and refreshed with each new edition.
Boeing at $231: The Math Behind a Recovery Story the Market Has Already Priced
For most of the past five years, Boeing has been a company in the middle of a slow-motion correction. A...
American Express Is Spending More to Earn More. The Filing Says Both Are Working.
In one breath The Q2 2026 10-Q filed July 24 shows American Express growing revenue at the fastest pace in...
Energy is up 14.7%. Jobs just turned negative. The same economy produced both.
Four years ago, inflation was the only story in America. The Consumer Price Index hit a number not seen since...
Evidence Sheet: Tonix Pharmaceuticals Holding (TNXP)
The standing BullScope yardsticks for Tonix Pharmaceuticals Holding, computed from official filings and refreshed with each new edition.
UPS: The Margin Story the Filings Tell vs. the One the Market Is Buying
A stock trading at a trailing earnings multiple well above its own decade average. A business whose net margin has...
Tonix’s TONMYA sales nearly triple in Q2 as payer coverage reaches 43% of U.S. lives
Tonix Pharmaceuticals reported second-quarter 2026 net sales of approximately $11 million for TONMYA, its fibromyalgia treatment, represent
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.